SERUM FREE LIGHT CHAIN DIFFERENCE (DSFLC) AS A ROBUST PREDICTOR FOR MULTIPARAMETER FLOW CYTOMETRY-BASED MINIMAL RESIDUAL DISEASE POSITIVITY IN MULTIPLE MYELOMA: A COHORT STUDY GUIDING OPTIMAL MONITORING STRATEGIES

EHA Library, Fan Zhang, 4160145

DREAMM-7 STUDY OF BELANTAMAB MAFODOTIN + BORTEZOMIB + DEXAMETHASONE VS DARATUMUMAB + BORTEZOMIB + DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A HIGH-RISK CYTOGENETIC SUBGROUP ANALYSIS

EHA Library, María-Victoria Mateos, 4160146

DREAMM-8 STUDY OF BELANTAMAB MAFODOTIN + POMALIDOMIDE + DEXAMETHASONE VS POMALIDOMIDE + BORTEZOMIB + DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A HIGH-RISK CYTOGENETIC SUBGROUP ANALYSIS

EHA Library, Meletios Dimopoulos, 4160148

FIRST RESULTS FROM REALITAL: A EUROPEAN MULTI-COUNTRY OBSERVATIONAL RETROSPECTIVE STUDY OF TALQUETAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA OUTSIDE OF CLINICAL TRIALS

EHA Library, K. Martin Kortüm, 4160149

IMPACT OF SELINEXOR DOSE REDUCTIONS ON SELINEXOR, BORTEZOMIB, DEXAMETHASONE (SVD) OUTCOMES IN PATIENTS (PTS) WITH LENALIDOMIDE (LEN)-REFRACTORY MULTIPLE MYELOMA (MM): BOSTON TRIAL SUBGROUP ANALYSIS

EHA Library, Sosana Delimpasi, 4160150

TO TREAT OR NOT? A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED STUDIES ON SMOLDERING MULTIPLE MYELOMA

EHA Library, Ioannis Ntanasis-Stathopoulos, 4160151

HIGHER USE OF HDT/ASCT IN FIRST-LINE LEADS TO SUPERIOR SURVIVAL IN MULTIPLE MYELOMA PATIENTS AGED 66-70: REAL-WORLD EVIDENCE FROM THE NETHERLANDS

EHA Library, Koen Klomberg, 4160152

RISK FACTORS AND MODES OF PROGRESSION IN SOLITARY BONE PLASMACYTOMA WITH OR WITHOUT MINIMAL MARROW INVOLVEMENT

EHA Library, Kenneth Jin Chang Lim, 4160153

TALQUETAMAB IMMUNOGENICITY AND IMPACT ON EXPOSURE, EFFICACY, AND SAFETY: ANALYSES FROM PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN MONUMENTAL-1

EHA Library, Indrajeet Singh, 4160154

RESUMPTION OF BONE-MODIFYING AGENTS IN RELAPSED MULTIPLE MYELOMA AND PATIENT OUTCOMES: A REAL-WORLD ANALYSIS

EHA Library, Malcolm Su, 4160155

THE ANTI-BCMA ANTIBODY-DRUG CONJUGATE HDP-101 WITH A NOVEL AMANITIN PAYLOAD SHOWS PROMISING DATA IN RELAPSED/ REFRACTORY MULTIPLE MYELOMA IN A PHASE 1/2A CLINICAL TRIAL AS IT ADVANCES INTO COHORT 7.

EHA Library, Shambavi Richard, 4160156

ISATUXIMAB, BORTEZOMIB, LENALIDOMIDE, DEXAMETHASONE (ISA-VRD) IN PATIENTS WITH TRANSPLANT-INELIGIBLE (TI) NEWLY DIAGNOSED MYELOMA (NDMM) AND PLASMACYTOMAS: IMROZ SUBGROUP ANALYSIS

EHA Library, Elena Zamagni, 4160157

SAFETY AND EFFICACY OF IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE AS 2ND OR 3RD LINE TREATMENT FOR TRIPLE EXPOSED MULTIPLE MYELOMA PATIENTS: A PHASE II MULTI-CENTER TRIAL (IPOD-790)

EHA Library, Tamir Shragai, 4160158

ISATUXIMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA WHO RELAPSED AFTER ONE LINE OF LENALIDOMIDE-CONTAINING THERAPY: A PHASE 2 STUDY BY THE GREEK MYELOMA STUDY GROUP

EHA Library, Evangelos Terpos, 4160159

ETOPOSIDE+CYTARABINE+PEGFILGRASTIM VS CYCLOPHOSPHAMIDE+GRANULOCYTE COLONY-STIMULATING FACTOR FOR STEM-CELL MOBILIZATION IN PATIENTS WITH MULTIPLE MYELOMA: A PHASE III TRIAL

EHA Library, Peipei Ye, 4160160

INTERIM ANALYSIS OF MRD-GUIDED MAINTENANCE THERAPY WITH BELANTAMAB MAFODOTIN AND LENALIDOMIDE AFTER AUTO-HCT IN NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Yosra Aljawai, 4160161

DEVELOPMENT AND VALIDATION OF A MULTIPLE MYELOMA-SPECIFIC COMORBIDITY INDEX FROM A KOREAN NATIONWIDE COHORT: CAREMM-2108

EHA Library, Sung-Soo Park, 4160162

WHOLE BODY MAGNETIC RESONANCE IMAGING FOR EARLY TREATMENT RESPONSE EVALUATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Ioannis Ntanasis-Stathopoulos, 4160163

HIGH PREVALENCE AND INCIDENCE OF ATRIAL FIBRILLATION AMONG PATIENTS WITH MULTIPLE MYELOMA. A POPULATION-BASED STUDY ON 8 672 PATIENTS DIAGNOSED 2008-2021 FROM THE SWEDISH MYELOMA REGISTRY.

EHA Library, Karin Larsson, 4160164

SEQUENTIAL BCMA CAR T-CELL THERAPY IN REFRACTORY MULTIPLE MYELOMA

EHA Library, Tim Richardson, 4160165

BASELINE OCULAR CONDITIONS AND INCIDENCE OF OCULAR EVENTS IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) FROM THE DREAMM-7 AND DREAMM-8 TRIALS OF BELANTAMAB MAFODOTIN (BELAMAF)

EHA Library, Dimopoulos Meletios, 4160166

REAL-WORLD TREATMENT PATTERNS AND CLINICAL OUTCOMES OF RELAPSED/REFRACTORY MULTIPLE MYELOMA IN ASIA - AN ASIAN MYELOMA NETWORK STUDY

EHA Library, Cinnie Soekojo, 4160167

DENOSUMAB IN MULTIPLE MYELOMA: LONGITUDINAL IMPACT ON BONE MINERAL DENSITY DYNAMICS AND PROGRESSION-FREE SURVIVAL — A MULTICENTER PROSPECTIVE COHORT ANALYSIS

EHA Library, Li Bao, 4160168

EXPOSURE-RESPONSE ANALYSES OF VARIOUS EFFICACY AND SAFETY ENDPOINTS IN SUPPORT OF REGISTRATIONAL DOSE SELECTION OF LINVOSELTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Swathi Namburi, 4160169

A RETROSPECTIVE STUDY OF ISATUXIMAB-POMALIDOMIDE-DEXAMETHASONE IN RELAPSED/REFRACTORY SYSTEMIC AL AMYLOIDOSIS

EHA Library, Sargam Vohra, 4160170

EFFICACY AND SAFETY OF ETENTAMIG, A BCMA X CD3 BISPECIFIC ANTIBODY, IN BLACK PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A POOLED ANALYSIS OF PHASE 1 TRIALS

EHA Library, Eben Lichtman, 4160171

SURVIVAL BENEFIT OF CILTACABTAGENE AUTOLEUCEL IN SECOND-LINE COMPARED WITH LATER-LINE TREATMENT OF LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: UPDATED TREATMENT POSITIONING MODEL ANALYSIS

EHA Library, Roberto Mina, 4160172

COMPREHENSIVE ANALYSIS OF SOLUBLE BCMA AS A TUMOR MARKER FOR MONITORING OF TUMOR BURDEN IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Masanori Toho, 4160173

QUADRUPLET DARATUMUMAB IN COMBINATION WITH BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE AS FRONT-LINE REGIMEN IMPROVED CLINICAL OUTCOMES IN HIGH-RISK MYELOMA PATIENTS IN CHINA: A MULTI-CENTERED PROSPECTIVE REAL-WORLD STUDY.

EHA Library, Junling Zhuang, 4160174

CLINICAL OUTCOMES OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WITH AND WITHOUT EXTRAMEDULLARY DISEASE

EHA Library, Peter Voorhees, 4160175

CLINICAL CHARACTERISTICS AND OUTCOMES OF UNTREATED AL-AMYLOIDOSIS PATIENTS: AN ANALYSIS OF A POPULATION-BASED REGISTRY

EHA Library, Flores Weverling, 4160176

REALITEC SUBGROUP ANALYSIS: A MULTI-COUNTRY OBSERVATIONAL RETROSPECTIVE STUDY OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA OUTSIDE OF CLINICAL TRIALS

EHA Library, Rakesh Popat, 4160177

EFFICACY AND SAFETY OF LESS FREQUENT DOSING WITH ELRANATAMAB (ELRA) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): A US SUBGROUP ANALYSIS FROM MAGNETISMM-3

EHA Library, Noopur Raje, 4160178

RETROSPECTIVE STUDY TO DESCRIBE THE CLINICAL CHARACTERISTICS, MANAGEMENT, AND OUTCOMES OF TALQUETAMAB IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA TREATED OUTSIDE CLINICAL TRIALS IN SPAIN.

EHA Library, Maria Jesus Blanchard Rodriguez, 4160179

INVESTIGATION INTO SECONDARY EXTRAMEDULLARY MYELOMA: A NOVEL FIVE-PREDICTOR SCORING SYSTEM HIGHLIGHTING DOUBLE-HIT CYTOGENETICS

EHA Library, Yi Tao, 4160180

TREATMENT PATTERNS AND EFFECTIVENESS IN AN ANTI-CD38 AND LENALIDOMIDE PRETREATED RRMM POPULATION: DATA FROM TWO REAL-WORLD DATASETS

EHA Library, Meera Mohan, 4160181

REAL-WORLD CLINICAL PRACTICE IN ITALIAN PATIENTS WITH MULTIPLE MYELOMA: PRELIMINARY ANALYSIS OF THE MY MYELOMA MULTICENTER REGISTRY

EHA Library, Giuseppe Bertuglia, 4160182

INDIRECT COMPARISON OF LINVOSELTAMAB VERSUS ELRANATAMAB FOR TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Sundar Jagannath, 4160183

DE-ESCALATED TECLISTAMAB DOSING IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: CZECH MYELOMA GROUP REAL-WORLD EVIDENCE STUDY

EHA Library, Martin Stork, 4160184

IMWG/ECOG FRAILTY ASSESSMENT IN NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS

EHA Library, Chengcheng Fu, 4160185

EARLY CLINICAL AND NON-GENETIC PREDICTORS OF FUNCTIONAL HIGH RISK NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

EHA Library, Massimo Offidani, 4160186

EUROPEAN CLINICAL VIEWS ON THE CHALLENGES OF TREATING PATIENTS WITH AUTOLOGOUS CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY AND BISPECIFIC ANTIBODIES IN MULTIPLE MYELOMA

EHA Library, Molly Purser, 4160187

STEM CELL TRANSPLANTATION IN FIT ELDERLY MULTIPLE MYELOMA PATIENTS IS SAFE AND EFFECTIVE, A REAL-WORLD AGE GROUP COMPARISON

EHA Library, Koen Klomberg, 4160188

IMPACT OF FREE LIGHT CHAINS BURDEN ON AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) OUTCOMES FOR AL AMYLOIDOSIS

EHA Library, Samer Srour, 4160189

BELANTAMAB FOR THE TREATMENT OF MULTIPLE MYELOMA: RESULTS FROM PART 1 OF THE FIRST-IN-HUMAN PHASE 1/2 DREAMM-20 TRIAL

EHA Library, Hang Quach, 4160190

MAGNETISMM-30: A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Alexander Lesokhin, 4160191

Identification of BARD1 mutation as a novel indicator for constructing a prognostic nomogram in multiple myeloma

EHA Library, Lin Ling, 4160192

RISK-SCORING MODEL FOR THE PROGNOSTIC IMPACT OF ADDITIONAL COPIES OF CHROMOSOME 1Q IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Yi Li, 4160193

REAL-WORLD EFFECTIVENESS OF BELANTAMAB MAFODOTIN, BCMA-CD3 BISPECIFIC ANTIBODIES AND TALQUETAMAB IN PATIENTS WITH TRIPLE-CLASS-EXPOSED MULTIPLE MYELOMA. FIRST RESULTS FROM THE DANISH ABCD-STUDY.

EHA Library, Astrid Hundebøll Torpe, 4160194

THE EFFECT OF SWITCHING TO LESS FREQUENT DOSING ON PATIENT-REPORTED OUTCOMES AMONG PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH ELRANATAMAB

EHA Library, Nizar J Bahlis, 4160195

PREDICTING MOBILIZATION OUTCOMES IN MULTIPLE MYELOMA PATIENTS USING A NOMOGRAM: A RETROSPECTIVE STUDY

EHA Library, Juan Li, 4160196

REAL-WORLD CHARACTERISTICS AND SAFETY AND EFFECTIVENESS OF TALQUETAMAB AMONG PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): AN ELECTRONIC MEDICAL RECORD AND CHART REVIEW STUDY

EHA Library, Cesar Rodriguez, 4160197

THE TREATMENT OF PATIENTS PROGRESSING AFTER LENALIDOMIDE MAINTENANCE: AN ITALIAN REAL-LIFE STUDY OF 284 CASES

EHA Library, Gregorio Barilà, 4160198

PREDICTING CARDIAC AND RENAL RESPONSE IN LIGHT CHAIN (AL) AMYLOIDOSIS USING AN ENSEMBLE MACHINE LEARNING MODEL

EHA Library, Louis Williams, 4160199

TOXICITY-RELATED TREATMENT CESSATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA - RISK FACTORS AND SURVIVAL: AN ANALYSIS FROM THE APAC AND ANZ MYELOMA AND RELATED DISEASES REGISTRY

EHA Library, Ji Hyun Lee, 4160200

EVALUATING THE IMPACT OF ETHNICITY ON THE OUTCOME OF MULTIPLE MYELOMA IN AUSTRALIA AND NEW ZEALAND: DATA FROM THE MYELOMA AND RELATED DISEASES REGISTRY

EHA Library, Silvia Ling, 4160201

RELAPSE FROM MEASURABLE DISEASE NEGATIVITY AS INDICATION FOR TREATMENT IN MULTIPLE MYELOMA: THE PHASE 3 REMNANT STUDY

EHA Library, Frida Bugge Askeland, 4160202

SINGLE AGENT ELRANATAMAB FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (R/R MM) - MULTI-CENTRE REAL-WORLD OUTCOMES FROM 5 UNITED KINGDOM (UK) SITES

EHA Library, Oliver Tomkins, 4160203

BURDEN OF ILLNESS IN PATIENTS WITH MULTIPLE MYELOMA (MM) WHO BECOME TRIPLE CLASS EXPOSED IN THE UK: RESULTS OF A RETROSPECTIVE ANALYSIS FROM THE RETINUE STUDY

EHA Library, Christopher Parrish, 4160204

ALTITUDE-1: REAL-WORLD TREATMENT PATTERNS ASSOCIATED WITH ELRANATAMAB AMONG PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Rahul Banerjee, 4160205

FUNCTIONAL GERIATRIC ASSESSMENT TESTS PREDICT TOXICITY RATES IN FUNCTIONAL HIGH RISK MYELOMA PATIENTS TREATED WITH DARATUMUMAB, CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN A PROSPECTIVE CLINICAL TRIAL

EHA Library, Yael Cohen, 4160206

TRIAL IN PROGRESS: QUINTESSENTIAL - A PHASE 2 STUDY OF ARLOCABTAGENE AUTOLEUCEL (ARLO-CEL) IN TRIPLE- AND QUAD-CLASS EXPOSED PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Krina Patel, 4160207

BROMODOMAIN AND EXTRA-TERMINAL (BET) PROTEIN INHIBITOR, INCB057643, IMPROVES BONE MARROW FUNCTION AND SHIFTS MEGAKARYOPOIESIS TO ERYTHROPOIESIS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS (MPNS)

EHA Library, Diana Alvarez Arias, 4160208

MODELING ADVANCED SYSTEMIC MASTOCYTOSIS: A NOVEL TRANSGENIC MOUSE LINE RECAPITULATES HUMAN DISEASE AND VALIDATES EFFICACY OF AVAPRITINIB

EHA Library, Martina Konantz, 4160209

BCL-XL INHIBITION POTENTIATES INTERFERON-INDUCED APOPTOSIS IN MPN STEM CELLS

EHA Library, Steven Lane, 4160210

INTERNATIONAL MULTICENTRE EVALUATION OF ARTIFICIAL INTELLIGENCE (AI) AUGMENTED FIBROSIS GRADING IN A REAL-WORLD, CLINICAL COHORT OF 1000 PATIENTS

EHA Library, Timothy Ebsworth, 4160211

3D MODELING OF BONE MARROW FIBROSIS AND ALTERED MEGAKARYOPOIESIS IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Christian Di Buduo, 4160212

DECIPHERING FIBROTIC NICHES IN MPN USING NICHESPHERE: A CELLULAR INTERACTION MAP OF BONE MARROW FIBROSIS

EHA Library, Hélène Gleitz, 4160213

CLONAL EVOLUTION DURING MPN TRANSFORMATION IS SHAPED BY A COMPLEX INTERPLAY BETWEEN MUTATION ACQUISITION, GENETIC INTERACTIONS, AND ALLELIC DOSAGE EVENTS

EHA Library, Noushin Farnoud, 4160214

THE DYNAMIC LANDSCAPE OF IMMUNE ENVIRONMENT FOR MM PATIENTS RECEIVING T CELL REDIRECTING THERAPIES

EHA Library, Jin Lu, 4160215

A NOVEL JAK2 INHIBITOR OB756 INHIBITS MEGAKARYOPOIESIS DIFFERENTIATION AND PROPLATELET BIOGENESIS VIA PI3K-AKT SIGNALING PATHWAY IN PATIENTS WITH PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Jian Huang, 4160216

DECIPHERING THE ENHANCER LANDSCAPE OF PTPN11-MUTANT JUVENILE MYELOMONOCYTIC LEUKEMIA

EHA Library, Noel Gómez-Molina, 4160217

CLONAL DYNAMICS AND COMPLEXITY OF HEMATOPOIETIC STEM CELLS CO-MUTATED IN CALR AND TP53 DURING THE TRANSFORMATION OF CLASSICAL MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Syrine Bel Haj Yahia, 4160218

MACROPHAGE POLARIZATION AND PHAGOCYTIC ACTIVITY IN PTPN11-MUTATED JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML): IMPLICATIONS FOR IMMUNE EVASION AND THERAPEUTIC TARGETING

EHA Library, Jun Wang, 4160219

DIETARY IRON AFFECTS HAEMATOLOGY AND BONE HEALTH IN A MOUSE MODEL OF POLYCYTHAEMIA VERA

EHA Library, Cavan Bennett, 4160220

TRANSCRIPTIONAL REPROGRAMMING OF SPLENIC ENDOTHELIAL CELLS IN MYELOFIBROSIS

EHA Library, Francesca Lazzaroni, 4160222

IMMUNE-MEGAKARYOCYTES ARE RESPONSIBLE FOR THE PATHOLOGICAL INTERLEUKIN-8 DEPENDENT EMPERIPOLESIS WITH NEUTROPHILS ASSOCIATED WITH MYELOFIBROSIS IN GATA1LOW MICE

EHA Library, Mario Falchi, 4160223

THE INFLAMMASOME NEGATIVELY MODULATES HEME OXYGENASE 1 CONTRIBUTING TO BONE MARROW FIBROSIS IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Jessica Ferrigno, 4160224

HYDROXYUREA DRIVES CLONAL SELECTION OF TP53 MUTATED CELLS IN MYELOPROLIFERATIVE NEOPLASMS (MPN)

EHA Library, Nabih Maslah, 4160225

JAK2 V617F VAF AND PRESENCE OF COPY NEUTRAL-LOH AT CHROMOSOME 9P (CHR9P) PREDICTS TRANSFORMATION TO MYELOFIBROSIS (MF) IN PATIENTS WITH POLYCYTHEMIA VERA (PV) ENROLLED IN REVEAL

EHA Library, Stephen Oh, 4160226

DECODING THE SUCNR1/HIF-1α /TNF-α AXIS: HOW MONOCYTES FUEL MYELOFIBROSIS IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Jieyu Wang, 4160227

THE CLONAL ORIGIN AND EVOLUTION OF HIGH-RISK MULTISYSTEM HISTIOCYTOSIS IN ADULTS

EHA Library, Kudzai Nyamondo, 4160228

THROMBOCYTOPENIA IN MYELOFIBROSIS (MF) IS CHARACTERIZED BY INFLAMMATORY MEGAKARYOCYTES WITH REDUCED G6B EXPRESSION THROMBOCYTOPENIA IN MYELOFIBROSIS IS CHARACTERIZED BY INFLAMMATORY MEGAKARYOCYTES WITH REDUCED G6B EXPRESSION

EHA Library, Lilian Varricchio, 4160229

THE SPATIAL DYSREGULATION OF MICROENVIRONMENT INVOLVING TENASCIN-C EXPRESSING CELLS CAN BE A CLINICALLY APPLICABLE MARKER FOR FIBROSIS PROGRESSION IN THE PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS.

EHA Library, Keiki Nagaharu, 4160230

POLA-R-CHP PERFORMED WELL IN POLARIX TRIAL-INELIGIBLE AND LOW RISK (IPI 0-1) PATIENTS WITH PREVIOUSLY UNTREATED DLBCL: A PROSPECTIVE OBSERVATIONAL STUDY

EHA Library, Yuhong Ren, 4160390

THE ABSOLUTE MONOCYTE AND LYMPHOCYTE PROGNOSTIC MODEL IDENTIFIES HIGH-RISK PATIENTS AND PREDICTS OUTCOMES IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

EHA Library, Wenhui Guo, 4160391

REAL WORLD DATA ON USE OF RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTED PATIENTS.

EHA Library, Lay Khandwala, 4160392

SINGLE-CELL ATLAS OF PRIMARY CNS LYMPHOMA REVEALS AN IMMUNE-RICH TUMOUR MICROENVIRONMENT MODULATED BY ENDOTHELIAL CELLS AND CANCER-ASSOCIATED FIBROBLASTS

EHA Library, Keir Pickard, 4160393

SINGLE-CELL RNA SEQUENCING OF PERIPHERAL BLOOD REVEALS IMMUNE CELL SIGNATURES IN EBV-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, QingQing Luo, 4160394

STROMAL CELL DIVERSITY IN ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA THROUGH SPATIAL TRANSCRIPTOME ANALYSIS AT SINGLE CELL RESOLUTION

EHA Library, Yuki Shimizu, 4160395

CD73 MODULATES IMMUNE ESCAPE VIA TRYPTOPHAN METABOLIC REPROGRAMMING IN DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Yingfang Feng, 4160396

CLINICAL IMPACT OF UNTARGETED BASELINE PLASMA METABOLOMICS IN NEWLY DIAGNOSED DIFFUSE LARGE B CELL LYMPHOMA

EHA Library, Riccardo Dondolin, 4160397

TARGETING MYH9-PRC1 AXIS EXERTS ANTI-TUMOR EFFECTS IN DIFFUSE LARGE B-CELL LYMPHOMA BY REGULATING PINK1/PARKIN-MEDIATED MITOPHAGY

EHA Library, Shunfeng Hu, 4160398

MULTI-OMICS ARCHITECTURE OF PLASMABLASTIC LYMPHOMA: EBV-MEDIATED AND GENOTYPE-SPECIFIC EFFECTS ON THE TUMOR MICROENVIRONMENT AND THERAPEUTIC VULNERABILITIES

EHA Library, Niklas Gebauer, 4160399

CHARACTERIZING TUMOR MICROENVIRONMENT HETEROGENEITY IN EBV+NTNKL VS ENKTCL USING SPATIAL TRANSCRIPTOMICS AND MIF

EHA Library, Siyu Qian, 4160400

IDENTIFICATION OF PLASMA PROTEINS ASSOCIATED WITH DIFFUSE LARGE B-CELL LYMPHOMA: A UK BIOBANK-BASED PROSPECTIVE STUDY

EHA Library, QingQing Luo, 4160401

WHOLE-GENOME SEQUENCING REVEALS THREE FOLLICULAR LYMPHOMA SUBTYPES WITH DISTINCT CELL-OF-ORIGIN AND PATIENT OUTCOMES

EHA Library, Weicheng Ren, 4160402

INACTIVATION OF CYLD INDUCES THE EXPANSION OF SPLENIC MARGINAL ZONE PRECURSOR B CELLS

EHA Library, Athanasios Pseftogkas, 4160403

NOVEL ROLE OF CHIDAMIDE IN TAM REPROGRAMMING AND IMMUNOTHERAPY ENHANCEMENT THROUGH RNA SPLICING

EHA Library, Caiqin Wang, 4160404

LONGITUDINAL TARGETED CTDNA ANALYSIS TO ASSESS CD20 AND BAFF MUTATIONS IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FL OR DLBCL PROGRESSING ON ODRONEXTAMAB TREATMENT IN THE ELM-2 STUDY

EHA Library, Stefano Luminari, 4160405